Positron emission tomography using 2-deoxy-2-[18 F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods

Molecular Imaging and Biology

Volumn 5, Issue 5, 2003, Pages 337-346

  Kroep, Judith R ^a   Van Groeningen, Cornelis J ^a   Cuesta, Miguel A ^b   Craanen, Mike E ^b   Hoekstra, Otto S ^b   Comans, Emile F I ^b   Bloemena, Elisabeth ^b   Hoekstra, Corneline J ^b   Golding, Richard P ^b   Twisk, Jos W R ^b   Peters, Godefridus J ^a   Pinedo, Herbert M ^a   Lammertsma, Adriaan A ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Medical Oncology ^*  (Netherlands)

Author keywords

EUS; FDG; Positron emission tomography

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY WEIGHT; CANCER ADJUVANT THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MONITORING; DRUG RESPONSE; DRUG UPTAKE; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MALE; NONLINEAR REGRESSION ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR CELL; VOMITING;

ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LINEAR MODELS; ROC CURVE; STOMACH NEOPLASMS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0346562891     PISSN: 15361632     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mibio.2003.09.007     Document Type: Article

References (43)

1. Earlam R. Cunha-Melo J.R. Oesophageal squamous cell carcinoma: II. A critical review of radiotherapy Br. J. Surg. 67 1980 457-461
2. Muller J.M. Erasmi H. Stelzner M. et al Surgical therapy of esophageal carcinoma Br. J. Surg. 77 1990 845-857
3. Roth J.A. Putnam Jr. J.B. Rich T.A. Forastiere A.A. Cancer of the esophagus De Vita V.T.Jr. Hellman S. Rosenberg S.A. 5th ed. Cancer principles and practice of oncology vol. 1 1997 980-1021 Lippincott-Raven Philadelphia
4. Law S.Y. Fok M. Wong J. Pattern of recurrence after esophageal resection for cancer: clinical implications Br. J. Surg. 835 1996 107-111
5. Kelsen D.P. Ginsberg R. Pajak T.F. et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer N. Engl. J. Med. 339 1998 19791984
6. Clark P. Surgical resection with or without pre-operative chemotherapy in esophageal cancer. An updated analysis of a randomized controlled trial conducted by the UK Medical Research Council Upper GI Tract Cancer Group Proc. Am. Soc. Clin. Oncol. 20 2001 126a (abstract 502)
7. Wolfman N.T. Scharling E.S. Chen M.Y.M. Esophageal squamous carcinoma Radiol. Clin. North Am. 32 1994 1183-1201
8. Van Dam J. Endoscopic evaluation of the patients with esophageal cancer [review] Chest Suppl. 4 1997 184-190
9. Hordijk M.L. Kok T.C. Wilson J.H. Mulder A.H. Assessment of response of esophageal cancer to induction therapy Endoscopy. 25 1993 592-596
10. Ng C.S. Husband J.E. MacVicar A.D. Ross P. Cunningham D.C. Correlation of CT with histopathological findings in patients with gastric and gastro-esophageal carcinomas following neoadjuvant chemotherapy Clin. Radiol. 53 1998 422-427
11. Fukunaga T. Okazumi S. Koide Y. Isono K. Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET J. Nucl. Med. 39 1999 102-107
12. Flamen P. Lerut A. Van Cutsem E. et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma J. Clin. Oncol. 18 2000 3202-3210
13. Young H. Baum R. Cremerius U. et al. Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations Eur. J. Cancer. 35 1999 1773-1782
14. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J. Clin. Oncol. 18 2000 1676-1688
15. Couper G.W. McAteer D. Wallis F. et al. Detection of response to chemotherapy using positron emission tomography in patients with esophageal and gastric cancer Br. J. Surg. 85 1998 1403-1406
16. Weber W.A. Ott K. Becker K. et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J. Clin. Oncol. 12 2001 3058-3065
17. Hoekstra C.J. Paglianiti I. Hoekstra O.S. et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods Eur. J. Nucl. Med. 27 2000 731-743
18. Hoekstra C.J. Hoekstra O.S. Stroobants S.G. et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG-PET J. Nucl. Med. 43 2002 1304-1309
19. Mandard A.M. Chasle J. Marnay J. et al. Autopsy findings in 111 cases of esophageal cancer Cancer 48 1981 329-335
20. Boellaard R. Van lingern A. Lammertsma A.A. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic pet: quantitative characteristics and effects on kinetic modeling J. Nucl. Med. 42 2001 808-817
21. Hoekstra C.J. Hoekstra O.S. Lammertsma A.A. On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies Eur. J. Nucl. Med. 26 1999 1489-1492
22. Van der Weerdt A.P. Klein L.J. Boellaard R. Visser C.A. Visser F.C. Lammertsma A.A. Image-derived input functions for determination of Mrglu in cardiac 18F-FDG PET scans J. Nucl. Med. 42 2001 1622-1629
23. Sadato N. Tsuchida T. Nakamura S. et al. Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake in tumors Eur. J. Nucl. Med. 25 1998 559-564
24. Hunter G.J. Hamberg L.M. Alpert N.M. Choi N.C. Fischman A.J. Simplified measurement of deoxyglucose utilization rate J. Nucl. Med. 37 1996 950-955
25. Huang S.C. Phelps M.E. Hoffman E.J. Sideris K. Selin C.J. Kuhl D.E. Noninvasive determination of local cerebral metabolic rate of glucose in man Am. J. Physiol. 238 1980 69-82
26. 18F]2-fluoro-2-deoxy-D-glucose: a comparison of different analytical methods J Cereb. Blood Flow Metab. 7 1986 161-172
27. Patlak C.S. Blasberg R.G. Fenstermacher J.D. Graphic evaluation of blood-to-brain transfer constants from multiple-time uptake data J. Cereb. Blood Flow Metab. 3 1983 1-7
28. Goldstein H. Multilevel statistical methods 1995 Edward Arnold London
29. 18F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods Eur. J. Nucl. Med. Mol. Imaging. 30 2003 674-681
30. Ilson D.H. Saltz L. Enzinger P. et al. Phase II trial of weekly irinothecan plus cisplatin in advanced esophageal cancer J. Clin. Oncol. 17 1999 3270-3275
31. Ilson D.H. Forastiere A. Arquette M. et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus Cancer J. 6 2000 316-323
32. Weber W.A. Ziegler S.I. Thodtmann R. Hanauske A.R. Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET J. Nucl. Med. 40 1999 1771-1777
33. Minn H. Zasadny K.R. Quint L.E. Wahl R.L. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy- D-glucose uptake at PET Radiology. 196 1995 167-173
34. Brugge W.R. Lee M.J. Carey R.W. Mathisen D.J. Endoscopic ultrasound staging criteria for esophageal cancer Gastrointest. Endosc. 45 1997 147152
35. Willis J. Cooper G.S. Isenberg G. et al. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma Gastrointest. Endosc. 55 2002 655-661
36. Kok T.C. Chemotherapy in esophageal cancer Cancer Treat. Rev. 23 1997 65-85
37. Walsh T.N. Noonan N. Hollywood D. Kelly A. Keeling N. Hennessy T.P.J. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma N. Engl. J. Med. 335 1996 462-467
38. Sandler A.B. Kindler H.L. Einhorn L.H. et al. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction Ann. Oncol. 11 2000 1161-1164
39. Bergman A.M. Ruiz van Haperen V.W.T. Veerman G. et al. Synergistic interaction between gemcitabine and cisplatin in vitro Clin. Cancer Res. 2 1996 521-530
40. Van Moorsel C.J.A. Pinedo H.M. Veerman G. et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines Br. J. Cancer. 80 1999 981-990
41. Kroep J.R. Peters G.J. van Moorsel C.J.A. et al. A schedule finding phase I/II study Ann. Oncol. 10 1999 1503-1510
42. Kroep J.R. Pinedo H.M. Giaccone G. Van Bochove A. Peters G.J. Van Groeningen C.J. Phase II study of cisplatin preceding gemcitabine in patients with advanced esophageal cancer Proc. ASCO. 19 2000 266 (abstract 1033)
43. Honkoop A.H. Luyks-de Bakker S.A. Hoekman K.et al Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer Ann. Oncol. 4 1999 106-111